FR2483234A2 - Composition ophtalmique contenant un activateur du plasminogene - Google Patents
Composition ophtalmique contenant un activateur du plasminogene Download PDFInfo
- Publication number
- FR2483234A2 FR2483234A2 FR8011911A FR8011911A FR2483234A2 FR 2483234 A2 FR2483234 A2 FR 2483234A2 FR 8011911 A FR8011911 A FR 8011911A FR 8011911 A FR8011911 A FR 8011911A FR 2483234 A2 FR2483234 A2 FR 2483234A2
- Authority
- FR
- France
- Prior art keywords
- plasminogen activator
- eye
- composition according
- composition containing
- ophthalmic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 102000001938 Plasminogen Activators Human genes 0.000 title claims abstract description 9
- 108010001014 Plasminogen Activators Proteins 0.000 title claims abstract description 9
- 229940127126 plasminogen activator Drugs 0.000 title claims abstract description 9
- 210000000416 exudates and transudate Anatomy 0.000 claims description 5
- 239000003889 eye drop Substances 0.000 claims description 5
- 229940012356 eye drops Drugs 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 230000002924 anti-infective effect Effects 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 229960005475 antiinfective agent Drugs 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 238000004140 cleaning Methods 0.000 abstract description 4
- 239000000470 constituent Substances 0.000 abstract 1
- 102000009123 Fibrin Human genes 0.000 description 7
- 108010073385 Fibrin Proteins 0.000 description 7
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 7
- 229950003499 fibrin Drugs 0.000 description 7
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
- A61L12/082—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances in combination with specific enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Eyeglasses (AREA)
- Detergent Compositions (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8011911A FR2483234A2 (fr) | 1980-05-29 | 1980-05-29 | Composition ophtalmique contenant un activateur du plasminogene |
| AT81400853T ATE6590T1 (de) | 1980-05-29 | 1981-05-27 | Verwendung von ophthalmischen zusammensetzungen, die einen plasminogenaktivator enthalten, zur reinigung von kontaktlinsen. |
| EP81400853A EP0041449B1 (fr) | 1980-05-29 | 1981-05-27 | Application d'une composition ophtalmique contenant un activateur du plasminogène, au nettoyage des lentilles cornéennes |
| DE8181400853T DE3162616D1 (en) | 1980-05-29 | 1981-05-27 | Application of an ophthalmic composition containing a plasminogen activator to contact lenses cleaning |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8011911A FR2483234A2 (fr) | 1980-05-29 | 1980-05-29 | Composition ophtalmique contenant un activateur du plasminogene |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2483234A2 true FR2483234A2 (fr) | 1981-12-04 |
| FR2483234B2 FR2483234B2 (OSRAM) | 1983-12-23 |
Family
ID=9242458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8011911A Granted FR2483234A2 (fr) | 1980-05-29 | 1980-05-29 | Composition ophtalmique contenant un activateur du plasminogene |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0041449B1 (OSRAM) |
| AT (1) | ATE6590T1 (OSRAM) |
| DE (1) | DE3162616D1 (OSRAM) |
| FR (1) | FR2483234A2 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3512908A1 (de) * | 1985-04-11 | 1986-10-23 | Behringwerke Ag, 3550 Marburg | Gewebe-plasminogenaktivator (t-pa) enthaltendes mittel |
| US4889722A (en) * | 1985-12-16 | 1989-12-26 | Ethicon, Inc. | Method for inhibiting post-surgical adhesion formation by the topical administration of tissue plasminogen activator |
| ZA869434B (en) * | 1985-12-16 | 1988-07-27 | Ethicon Inc | Method for inhibiting post-surgical adhesion formation by the topical administration of tussue plasminogen activator |
| CA1336396C (en) * | 1988-07-25 | 1995-07-25 | Kiyoshi Kita | Intraocular anticoagulant including antithrombin iii and method of administration |
| US5141928B1 (en) * | 1989-12-20 | 1995-11-14 | Brujo Inc | Ophthalmic medication |
| DE19606551C2 (de) * | 1996-02-22 | 2000-06-08 | Basotherm Gmbh | rt-PA zur Prävention des Nachstars nach Kataraktoperation |
| WO1997031660A1 (en) * | 1996-02-29 | 1997-09-04 | Vision Pharmaceuticals L.P. | Contact lens treating compositions, methods of treatment, and novel lenses |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB872146A (en) * | 1958-01-06 | 1961-07-05 | Innerfield Irving | Emzymic composition |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3324002A (en) * | 1962-09-17 | 1967-06-06 | Armour Pharma | Anti-inflammatory preparations containing proteolytic enzymes and adrenal glucocorticoids |
| US3910296A (en) * | 1973-04-20 | 1975-10-07 | Allergan Pharma | Method of removing proteinaceous deposits from contact lenses |
| FR2252842B1 (OSRAM) * | 1973-12-03 | 1977-11-04 | Fabre Sa Pierre | |
| FR2462165A2 (fr) * | 1973-12-03 | 1981-02-13 | Fabre Sa Pierre | Procede perfectionne de preparation d'activateur du plasminogene |
| FR2310133A2 (fr) * | 1975-05-05 | 1976-12-03 | Fabre Sa Pierre | Nouveau medicament comportant un activateur du plasminogene perfectionne |
| CA1154671A (fr) * | 1979-07-27 | 1983-10-04 | Lucien D. D'hinterland | Separation d'un activateur tissulaire du plasminogene |
-
1980
- 1980-05-29 FR FR8011911A patent/FR2483234A2/fr active Granted
-
1981
- 1981-05-27 DE DE8181400853T patent/DE3162616D1/de not_active Expired
- 1981-05-27 EP EP81400853A patent/EP0041449B1/fr not_active Expired
- 1981-05-27 AT AT81400853T patent/ATE6590T1/de not_active IP Right Cessation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB872146A (en) * | 1958-01-06 | 1961-07-05 | Innerfield Irving | Emzymic composition |
Non-Patent Citations (1)
| Title |
|---|
| CA1978 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0041449A1 (fr) | 1981-12-09 |
| EP0041449B1 (fr) | 1984-03-14 |
| FR2483234B2 (OSRAM) | 1983-12-23 |
| ATE6590T1 (de) | 1984-03-15 |
| DE3162616D1 (en) | 1984-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3855096T2 (de) | Hemmung von arteriellem thrombotischen Verschluss oder von Thrombo-Embolismus | |
| EP1247532B1 (en) | Composition promoting lacrimal secretion | |
| EP0420600B1 (en) | Use of protease inhibitors as antiexudative, antiphlogistic and antimicrobial agents | |
| US5518732A (en) | Bio-erodible ophthalmic shield | |
| WO1997039769A1 (fr) | Composition de medicament comprenant de l'albumine en tant que principe actif | |
| EP0346241B1 (fr) | Procédé de préparation d'une fraction concentrée en facteur Vlla et son application à titre de médicament | |
| FR2483234A2 (fr) | Composition ophtalmique contenant un activateur du plasminogene | |
| Unal et al. | The efficacy of plasminogen-urokinase combination in inducing posterior vitreous detachment | |
| Dosekun et al. | Ancrod in systemic lupus erythematosus with thrombosis: clinical and fibrinolysis effects | |
| US6174859B1 (en) | Method of treatment | |
| US20020091100A1 (en) | Cromolyn for eye and ear infections | |
| CA2443728C (fr) | Composition pharmaceutique a base de macrolides pour application locale en ophtalmologie | |
| JPH10500684A (ja) | 非ステロイド系抗炎症性眼科用懸濁液剤 | |
| JP2009501725A (ja) | 糖尿病の眼科合併症の予防及び治療 | |
| JPH08510731A (ja) | 治療使用のためのその場で生成するゲル | |
| DE69528573T2 (de) | Verwendung einer Zubereitung enthaltend einen Plasminogen-Aktivator für die Verbesserung der Wundheilung | |
| RU2197923C1 (ru) | Фармацевтическая композиция для лечения отеков роговицы "осмогель" | |
| JPS6399013A (ja) | 血流増強用眼用組成物 | |
| KR20050102653A (ko) | 병적 눈 혈관신생 치료용 글루코코르티코이드 제제 | |
| JP3742675B2 (ja) | 虚血−再灌流障害の予防および治療薬 | |
| CN1066328C (zh) | 阿尔加托品烷在药物制备中的应用 | |
| EP0083261B1 (fr) | Composition thérapeutique, à base d'inosine monophosphaté, pour le traitement des troubles d'accommodation de l'oeil | |
| RU2049450C1 (ru) | Способ лечения язвенного кератита | |
| TEMPEA et al. | Cavernous sinus thrombosis | |
| CA2243161A1 (en) | Use of interferon-beta to treat retinal edema |